Summary
Cencora, Inc. (formerly AmerisourceBergen Corporation) reported solid revenue growth in its first quarter of fiscal year 2021, with a 3.7% increase year-over-year to $49.2 billion. This growth was primarily driven by its Pharmaceutical Distribution Services segment, which saw higher sales of specialty products, including COVID-19 treatments. The company also experienced a significant improvement in operating income, which more than doubled to $624.3 million, benefiting from increased gross profit and reduced operating expenses compared to the prior year. A key development highlighted in the filing is the January 2021 agreement to acquire a majority of Walgreens Boots Alliance's (WBA) Alliance Healthcare businesses for approximately $6.5 billion. This strategic move is expected to expand Cencora's global reach and enhance its existing manufacturer services platform. The company also secured new debt financing and issued senior notes to fund this acquisition, signaling a proactive approach to growth and capital management.
Financial Highlights
56 data points| Revenue | $49.15B |
| Cost of Revenue | $47.62B |
| Gross Profit | $1.53B |
| SG&A Expenses | $730.08M |
| Operating Income | $624.35M |
| Net Income | $435.27M |
| EPS (Basic) | $2.12 |
| EPS (Diluted) | $2.10 |
| Shares Outstanding (Basic) | 204.92M |
| Shares Outstanding (Diluted) | 207.31M |
Key Highlights
- 1Revenue increased by 3.7% to $49.2 billion for the quarter ended March 31, 2021, compared to the prior year, driven by the Pharmaceutical Distribution Services segment.
- 2Operating income more than doubled, increasing by 101.7% to $624.3 million, due to higher gross profit and lower operating expenses.
- 3The company announced a significant agreement to acquire a majority of Walgreens Boots Alliance's (WBA) Alliance Healthcare businesses for approximately $6.5 billion.
- 4Cencora secured new debt financing, including $1.525 billion in senior notes and a $1.0 billion term loan, to fund the acquisition.
- 5Cash and cash equivalents increased significantly to $6.6 billion, up from $4.6 billion at the end of the prior fiscal year.
- 6The company continues to manage significant legal matters, notably the ongoing opioid litigation, for which a substantial accrual has been made.
- 7Gross profit increased by 10.5% to $1.53 billion, reflecting improved margins in key segments and favorable LIFO adjustments.